Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer

Shots:

• The P-III ALEX study involves assessing of Alecensa vs crizotinib in 303 treatment-naïve patients in a ratio (1:1) with ALK+ NSCLC whose tumors were characterized as ALK+ by the VENTANA ALK (D5F3) CDx Assay
• Updated results: OS @5yrs. (62.5% vs 45.5%); reduction in the risk of death in patients with/ without CNS metastases (42%/ 24%) respectively, updated data confirms Alecensa’s safety & tolerability. The updated data follows mPFS data, presented at ESMO 2019 which demonstrated 57% reduction in risk of disease worsening or death
• Alecensa (RG7853/AF-802/RO5424802/CH5424802) is a highly selective, CNS active, oral therapy, being developed for people with ALK+ NSCLC and has received approval in 88+ countries as 1L treatment for ALK+ m-NSCLC including in the US, EU, Japan and China

Click here ­to­ read full press release/ article | Ref: Roche | Image: Twitter